ArticleHistopathology2010
Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.
Article in Histopathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Archives of pathology & laboratory medicine · 2014Guideline
- A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer.Frontiers in oncology · 2021Review
- The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.British journal of cancer · 2019Article
- Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients.Molecular diagnosis & therapy · 2018Article
- Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.Breast cancer research and treatment · 2016Article
- Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.The journal of pathology. Clinical research · 2016Article
- Fixation strategies for retinal immunohistochemistry.Progress in retinal and eye research · 2015Review
- Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.British journal of cancer · 2014Article
- Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers.British journal of cancer · 2013Article
- Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2013Article
- Comparison of automated and manual FISH for evaluation of HER2 gene status on breast carcinoma core biopsies.BMC clinical pathology · 2013Article
- Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2013Review
- Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women.ISRN oncology · 2013Article
- Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing.International journal of breast cancer · 2013Article
- PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.BMC medical genomics · 2012Article
- Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization.BMC clinical pathology · 2012Article
- High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.Journal of cancer research and clinical oncology · 2012Article
- Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.Breast cancer research : BCR · 2012Article
- Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.The oncologist · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsFluorescence in situ hybridization (FISH) can be used to reveal several genomic imbalances relevant to proper cancer diagnosis and to the correct treatment regime. However, FISH requires expensive and advanced fluorescence microscopes in addition to expertise in fluorescence microscopy. To determine whether a newly developed dual-colour chromogenic in situ hybridization (CISH) method is a suitable alternative to FISH, we analysed the human epidermal growth factor receptor 2 gene (HER2) amplification level of 168 breast cancer specimens using dual-colour CISH and FISH and compared the results. METHODS AND
resultsWe found 100% agreement between HER2 status determined by FISH and dual-colour CISH. Furthermore, we observed that the time used to score slides was significantly reduced by 28% in dual-colour CISH compared with the FISH protocol. Concordance between HER2 protein status and dual-colour CISH or FISH was equally good with an overall agreement of 96.8%. Correlation between the HER2/centromere 17 gene ratios obtained with dual-colour CISH and FISH was highly significant with an overall correlation coefficient (rho) of 0.96.
conclusionsWe conclude that dual-colour CISH and bright field microscopy are excellent alternatives to FISH when analysing the HER2 status of primary breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.